Rigel Pharmaceuticals (RIGL) Net Income Growth (3y) (2013 - 2026)
Rigel Pharmaceuticals (RIGL) Net Income Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | 9.16% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | 79.26% |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | 47.10% |
| 10 | Rigel Pharmaceuticals | 700.67 Mn | 553.98 Mn | 54.21 Mn | 37.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.90% |
| Dec 31, 2025 | 476.24% |
| Sep 30, 2025 | 51.33% |
| Jun 30, 2025 | 85.84% |
| Mar 31, 2025 | 34.20% |
| Dec 31, 2024 | 38.11% |
| Sep 30, 2024 | 37.38% |
| Jun 30, 2024 | 57.89% |
| Mar 31, 2024 | -30.24% |
| Dec 31, 2023 | 26.00% |
| Sep 30, 2023 | 26.22% |
| Jun 30, 2023 | 27.85% |
| Mar 31, 2023 | -38.47% |
| Dec 31, 2022 | 27.11% |
| Sep 30, 2022 | 24.91% |
| Jun 30, 2022 | 23.96% |
| Mar 31, 2022 | -4.51% |
| Dec 31, 2021 | 57.13% |
| Sep 30, 2021 | 4.11% |
| Jun 30, 2021 | 18.59% |